Clinical Trials
128
86 active
Approvals
15
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
Active, not recruiting
85
66.4%
Completed
9
7.0%
Not yet recruiting
1
0.8%
Recruiting
32
25.0%
Unknown
1
0.8%
- A phase II clinical trial demonstrated that patients with alveolar soft part sarcoma can safely receive atezolizumab immunotherapy beyond the standard two-year treatment period without increased toxicity. - Among 17 patients treated for more than two years, only three experienced moderate-to-severe treatment-related adverse events, all of which were manageable and resolved with dose adjustments or additional medications. - The findings are particularly significant for adolescents and young adults with this ultra-rare cancer, who may require extended treatment periods and could live for many years with metastatic disease. - No patients discontinued treatment due to adverse events, and researchers observed no late toxicities typically associated with long-term immunotherapy use in other cancer types.
- A comprehensive scoping review of 40 clinical trials published in BMC Cancer reveals that metformin may modestly increase pathologic complete response rates in HER2-positive breast cancer patients when added to standard treatment regimens. - Observational evidence demonstrates that breast cancer patients with diabetes who received metformin showed improved survival outcomes, with hazard ratios suggesting nearly a 50% reduction in breast cancer-specific mortality compared to non-users. - Metformin's mechanism involves activating AMP-activated protein kinase (AMPK) and inhibiting the mTOR pathway, potentially enhancing the effectiveness of HER2-targeted therapies like trastuzumab and pertuzumab. - Despite promising preliminary results, most phase 3 trials have not yet shown statistically significant survival improvements, highlighting the need for more rigorous, subtype-focused investigations in HER2-positive disease.
- RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis. - The polymyositis therapeutic pipeline includes over 7 companies developing treatments, with emerging therapies like HuABC2, PF1801, PN-101, and M5049 advancing through clinical trials. - Polymyositis is a rare autoimmune disease causing inflammation and weakness of skeletal muscles, with current treatment options limited and high drug costs creating market barriers.
